Last updated on July 2019

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis


Brief description of study

The purpose of this study is to evaluate the efficacy of pimavanserin by comparing pimavanserin with placebo in preventing a relapse of psychotic symptoms in subjects with dementia-related psychosis and who were stabilized after 12 weeks of open label pimavanserin treatment.

Clinical Study Identifier: NCT03325556

Find a site near you

Start Over

ATP Clinical Research Inc.

Costa Mesa, CA United States
  Connect »

Neuro-Pain Medical Center

Fresno, CA United States
  Connect »

Bioclinica Research

Orlando, FL United States
  Connect »

Quantum Laboratories

Pompano Beach, FL United States
  Connect »

Acadia Hospital

Bangor, ME United States
  Connect »

Alzheimer Disease Center

Quincy, MA United States
  Connect »

Precise Research Centers

Flowood, MS United States
  Connect »

Clinical Research Professionals

Chesterfield, MO United States
  Connect »

Neurology Center of Las Vegas

Las Vegas, NV United States
  Connect »

Einstein Clinical, LLC

Phillipsburg, NJ United States
  Connect »

BioBehavioral Health

Toms River, NJ United States
  Connect »

Richmond Behavioral Associates

Staten Island, NY United States
  Connect »

Thomas Jefferson University

Philadelphia, PA United States
  Connect »

BG Neurology LLC

Spartanburg, SC United States
  Connect »

University of Virginia Adult Neurology

Charlottesville, VA United States
  Connect »

AD71, s.r.o.

Praha 10, Czechia
  Connect »

Crystal Comfort, s.r.o.

Vranov nad Toplou, Slovakia
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.